Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cytek Biosciences (CTKB) Income from Continuing Operations (2020 - 2025)

Historic Income from Continuing Operations for Cytek Biosciences (CTKB) over the last 6 years, with Q3 2025 value amounting to -$5.5 million.

  • Cytek Biosciences' Income from Continuing Operations fell 67147.34% to -$5.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.8 million, marking a year-over-year decrease of 2623.35%. This contributed to the annual value of -$6.0 million for FY2024, which is 5044.45% up from last year.
  • Cytek Biosciences' Income from Continuing Operations amounted to -$5.5 million in Q3 2025, which was down 67147.34% from -$5.6 million recorded in Q2 2025.
  • Cytek Biosciences' Income from Continuing Operations' 5-year high stood at $9.6 million during Q4 2024, with a 5-year trough of -$11.4 million in Q1 2025.
  • Moreover, its 5-year median value for Income from Continuing Operations was -$1.2 million (2021), whereas its average is -$1.9 million.
  • The largest annual percentage gain for Cytek Biosciences' Income from Continuing Operations in the last 5 years was 41914.16% (2022), contrasted with its biggest fall of 221568.63% (2022).
  • Over the past 5 years, Cytek Biosciences' Income from Continuing Operations (Quarter) stood at -$1.2 million in 2021, then surged by 419.14% to $3.7 million in 2022, then soared by 47.18% to $5.5 million in 2023, then soared by 75.49% to $9.6 million in 2024, then tumbled by 156.95% to -$5.5 million in 2025.
  • Its last three reported values are -$5.5 million in Q3 2025, -$5.6 million for Q2 2025, and -$11.4 million during Q1 2025.